Conatus Pharma's liver drug succeeds in mid-stage study

March 26, 2015 11:06 AM

16 0

(Reuters) - Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease.

The drug, emricasan, was tested in 38 patients with non-alcoholic fatty liver disease, including some sufferers of non-alcoholic steatohepatitis (NASH), a more severe form of the condition, the company said on Thursday.

Read more

To category page